Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200
Debt
Debt-to-Equity Ratio0.76
Current Ratio8.38
Quick Ratio8.34
Price-To-Earnings
Trailing P/E Ratio644.00
Forward P/E Ratio-135.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$507.67 million
Price / Sales13.93
Cash Flow$0.3808 per share
Price / Cash135.31
Book Value$3.36 per share
Price / Book15.33
Profitability
EPS (Most Recent Fiscal Year)$0.08
Net Income$-5,960,000.00
Net Margins-7.20%
Return on Equity-1.22%
Return on Assets-0.40%
Miscellaneous
Employees547
Outstanding Shares137,270,000
Market Cap$6.75 billion
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.20. The business had revenue of $117.75 million for the quarter, compared to the consensus estimate of $128.22 million. Ionis Pharmaceuticals had a negative return on equity of 1.22% and a negative net margin of 7.20%. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What price target have analysts set for IONS?
8 brokerages have issued twelve-month price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $30.00 to $75.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $52.3750 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.
What is the consensus analysts' recommendation for Ionis Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE) and Bausch Health Companies (BHC).
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 73)
- Dr. Brett P. Monia, Founder, COO and Sr. VP of Antisense Drug Discovery & Translational Medicine (Age 57)
- Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 56)
- Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 60)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 64)
Who are Ionis Pharmaceuticals' major shareholders?
Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (13.72%), Baillie Gifford & Co. (7.39%), BB Biotech AG (6.90%), BlackRock Inc. (5.62%), OppenheimerFunds Inc. (2.14%) and Wells Fargo & Company MN (0.96%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Which institutional investors are selling Ionis Pharmaceuticals stock?
IONS stock was sold by a variety of institutional investors in the last quarter, including Motley Fool Asset Management LLC, Pinnacle Associates Ltd., ARK Investment Management LLC, Renaissance Technologies LLC, Millennium Management LLC, California Public Employees Retirement System, GSA Capital Partners LLP and Tanaka Capital Management Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Which institutional investors are buying Ionis Pharmaceuticals stock?
IONS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., First Light Asset Management LLC, Peregrine Capital Management LLC, Motley Fool Wealth Management LLC, Los Angeles Capital Management & Equity Research Inc., Sicart Associates LLC, BB Biotech AG and BlackRock Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals.
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $51.52.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $6.75 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.
What is Ionis Pharmaceuticals' official website?
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
